The 2009 ISPAD Clinical Practice Consensus Guidelines have now been published as a compendium in a Supplement to Pediatric Diabetes. We thank the international writing teams for their efforts in writing and updating these guidelines. The editors have been: Ragnar Hanas, Kim Donaghue, Georgeanna Klingensmith and Peter GF Swift.
Click here to find the files.
Latest News
ISPAD´s prizes for 2009 were presented at the annual meeting in Ljubljana, Slovenia. The ISPAD Prize for Achievement is the Society’s highest honour. It is awarded to any individual who has made outstanding contributions in the areas of SCIENCE, EDUCATION or ADVOCACY which have had a major impact on childhood and adolescent diabetes. The ISPAD Prize for Achievement (sponsored by Eli Lilly) may be awarded to members or non-members of ISPAD.
The 2009 Prize for Achievement was awarded to Martin Silink, Sydney, Australia. The Lestradet Prize for Education and Advocacy (sponsored by Lifescan) was awarded to Viorel Serban, Timisoara, Romania and the Young Investigator Award (sponsored by Medtronic) was awarded to Jamil Malik, Amsterdam, The Netherlands.
The 2009 Prize for Achievement was awarded to Martin Silink, Sydney, Australia. The Lestradet Prize for Education and Advocacy (sponsored by Lifescan) was awarded to Viorel Serban, Timisoara, Romania and the Young Investigator Award (sponsored by Medtronic) was awarded to Jamil Malik, Amsterdam, The Netherlands.
Allan Drash, one of the leaders of ISPAD (formerly ISGD), has recently passed away. He has been a brilliant scientific advisor for many ISPAD members, a great educator to all those involved in diabetes care and an outstanding advocate for all issues concerning children with diabetes. He served on the first ISGD Advisory Council from 1976 – 1980, and was the second president of ISGD for two terms from 1981-1984-1987. Graduates of the Pittsburgh program headed by Allan Drash for more than a quarter century populate an astounding number of academic positions and especially division chief positions, and include many distinguished members of ISPAD. In 2006 he was awarded our highest honour, the ISPAD Prize of Achievement.
He will be remembered to those upcoming ISPAD generations not only for his numerous achievements but also through the ISPAD Allan Drash Fellowship. Starting in 2006, ISPAD has been awarding an annual 6 week clinical fellowship for applicants below 45 years in his name.
He will be remembered to those upcoming ISPAD generations not only for his numerous achievements but also through the ISPAD Allan Drash Fellowship. Starting in 2006, ISPAD has been awarding an annual 6 week clinical fellowship for applicants below 45 years in his name.
ISPAD supports statements of other societies such as the American Diabetes Association ADA, LWPES, FDA and European Medicines Agency EMEA that on the basis of the currently available data, a relationship between insulin glargine and cancer cannot be confirmed nor excluded, and the concerns require further in-depth evaluation.
ISPAD does not recommend that patients receiving insulin glargine should be switched to an alternative basal insulin. Also, with the current knowledge and the proven benefits of the drug particularly regarding the lower rate of hypoglycemia compared to human insulin, no reason for a recommendation not to start pediatric patients on glargine is warranted. Therapeutic alternatives may be considered in type 2 diabetic patients with preexisting cancer or an increased familial breast cancer risk. Patients and parents should be made aware that the link between insulin and cancer has been suggested but not proven, and only in adults with type 2 diabetes mellitus.
ISPAD supports further research into the long-term safety of all the insulin analogs. The full statement can be downloaded below.
ISPAD does not recommend that patients receiving insulin glargine should be switched to an alternative basal insulin. Also, with the current knowledge and the proven benefits of the drug particularly regarding the lower rate of hypoglycemia compared to human insulin, no reason for a recommendation not to start pediatric patients on glargine is warranted. Therapeutic alternatives may be considered in type 2 diabetic patients with preexisting cancer or an increased familial breast cancer risk. Patients and parents should be made aware that the link between insulin and cancer has been suggested but not proven, and only in adults with type 2 diabetes mellitus.
ISPAD supports further research into the long-term safety of all the insulin analogs. The full statement can be downloaded below.
This meeting in London Oct 25th was initiated by IDF/Life for a Child (www.lifeforachild.org) and hosted by Diabetes UK. A large number organizations and companies were represented. The aims were two-fold:
1. To find urgent but "temporary" humanitarian strategies to keep children with type 1 diabetes in developing countries alive.
2. To set the stage for longterm structural review of access to essential drugs and glucose monitoring supplies for all people with diabetes in developing countries.
The outcome was a huge success with pledges from the industry for supplying 5,500 children with insulin next year and 29,000 by 2015 and providing 1 million syringes. ISPAD pledged structural support and assistance in the training of pediatricians and healthcare professionals in childhood and adolescent diabetes through its membership network.
1. To find urgent but "temporary" humanitarian strategies to keep children with type 1 diabetes in developing countries alive.
2. To set the stage for longterm structural review of access to essential drugs and glucose monitoring supplies for all people with diabetes in developing countries.
The outcome was a huge success with pledges from the industry for supplying 5,500 children with insulin next year and 29,000 by 2015 and providing 1 million syringes. ISPAD pledged structural support and assistance in the training of pediatricians and healthcare professionals in childhood and adolescent diabetes through its membership network.
Download: Results_IDF_Access_Meeting.PDF